Effectiveness of increasing the scalp cooling duration to prevent alopecia during adjuvant chemotherapy for breast cancer: a randomized pilot study.
Support Care Cancer
; 32(7): 410, 2024 Jun 05.
Article
en En
| MEDLINE
| ID: mdl-38839667
ABSTRACT
PURPOSE:
Alopecia is a common side-effect of chemotherapy and can be extremely distressing to patients. Scalp cooling can be used to reduce hair loss, but the optimal duration of cooling remains unclear. Our aim was to determine whether increasing the duration of scalp cooling improves hair preservation.METHODS:
Patients with HER2-negative, non-metastatic, breast cancer received scalp cooling during adjuvant chemotherapy three cycles of epirubicin/cyclophosphamide (EC) followed by three cycles of paclitaxel. The patients were randomly assigned to two groups. Group A (n=18) wore a Paxman cooling cap during each infusion and for 30 min post-infusion while Group B (n=19) wore the cap from 30 min before to 2 h after each infusion. All patients were asked to complete a questionnaire recording hair loss/regrowth, adverse events, and quality of life. Success of treatment was defined as <50% hair loss.RESULTS:
The success rates after each of the three cycles did not differ significantly between the two groups (EC Group A 40%, Group B 44%; paclitaxel Group A 50%, Group B 36%; p>0.05). Hair regrowth was significantly higher in Group B at the 8-week follow-up, but not at the 6-month follow-up. Head discomfort affected more patients in Group B than in Group A during the first session (94% vs. 62%, respectively; p=0.039).CONCLUSION:
Long duration scalp cooling during chemotherapy might increase patients' discomfort and does not appear to improve hair preservation.Palabras clave
Texto completo:
1
Colección:
01-internacional
Banco de datos:
MEDLINE
Asunto principal:
Calidad de Vida
/
Cuero Cabelludo
/
Neoplasias de la Mama
/
Epirrubicina
/
Protocolos de Quimioterapia Combinada Antineoplásica
/
Paclitaxel
/
Ciclofosfamida
/
Alopecia
Límite:
Adult
/
Aged
/
Female
/
Humans
/
Middle aged
Idioma:
En
Revista:
Support Care Cancer
Asunto de la revista:
NEOPLASIAS
/
SERVICOS DE SAUDE
Año:
2024
Tipo del documento:
Article
País de afiliación:
Francia